The group will start a pivotal trial of samuraciclib following promising second-line results.
ApexOnco Front Page
Recent articles
Some time ago Opdivo beat Advetris in an NCI trial, and now Bristol files.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
So who else could be interested in the oestrogen degrader?
The recently unveiled conjugate DS3610a is to start phase 1.
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The companies clash over survival curve similarities – and differences.
